Drugs / MB-105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06534060 | Feb 2025 → Feb 2028 expected | T-cell non-Hodgkin lymphoma | March Biosciences Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-02-15 | Mustang Bio, Inc. | Results Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium mustangbio.com ↗
In the 100M cells plus lymphodepletion dose level, two patients experienced DLT of grade 3 non-infective cystitis and fatigue. |
| 2022-02-14 | Moleculin Biotech, Inc. | Results Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development moleculin.com ↗
Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2D), subject to final approval of the Safety Review Committee, and indicated no signs of cardiotoxicity (a common problem with currently prescribed anthracyclines). |
| 2020-10-26 | Mustang Bio, Inc. | Results Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer mustangbio.com ↗
We are encouraged by the initial data presented by City of Hope from the ongoing Phase 1 trial of Mustang’s CAR T cell therapy MB-105. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06534060 ↗ |
| Modality | Cell therapy | “MB-105 is a CAR T-cell therapy” NCT06534060 ↗ |
| Target | CD5 | “autologous T-cells that express a CD5 CAR.” NCT06534060 ↗ |